Linked Life Data

12230024

Source:http://linkedlifedata.com/resource/pubmed/id/12230024

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12230024rdf:typepubmed:Citationlld:pubmed
pubmed-article:12230024lifeskim:mentionsumls-concept:C1533719lld:lifeskim
pubmed-article:12230024lifeskim:mentionsumls-concept:C0524910lld:lifeskim
pubmed-article:12230024lifeskim:mentionsumls-concept:C0879626lld:lifeskim
pubmed-article:12230024lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:12230024lifeskim:mentionsumls-concept:C0752221lld:lifeskim
pubmed-article:12230024pubmed:issue2-3lld:pubmed
pubmed-article:12230024pubmed:dateCreated2002-9-16lld:pubmed
pubmed-article:12230024pubmed:abstractTextThe purpose of this study was to determine if the adverse effects of interferon (IFN) in hepatitis C patients could be reduced by treatment with Japanese Oriental (Kampo) medicine. Twelve patients with chronic hepatitis C were treated with a combination of IFN-beta and either Mao-to or Dai-seiryu-to (groups A and B), and 16 patients were treated with IFN-beta alone (group C). Mao-to was administered to eight patients and Dai-seiryu-to was administered to four in groups A and B, respectively. Adverse effects were evaluated by clinical and laboratory examinations. The severity of symptoms was daily self-classified into four categories (1: none, 2: very slight, 3: moderate, and 4: serious), using a questionnaire consisting of 29 items. Scores of symptom such as discomfort and fever in group A, and discomfort, general malaise, paresthesia and arthralgia in group B were significantly lower than those in group C (p < 0.05). In all patients, HCV-RNA was negative at the end of the treatment, and serum alanine aminotransferase (ALT) levels had normalized transiently in all group A and B patients with genotype 1b by 2 weeks after cessation of IFN treatment. This study indicates that Kampo medicines are useful for reducing the adverse effects accompanying IFN treatment in patients with chronic hepatitis C without reducing the antiviral effects.lld:pubmed
pubmed-article:12230024pubmed:languageenglld:pubmed
pubmed-article:12230024pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12230024pubmed:citationSubsetIMlld:pubmed
pubmed-article:12230024pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12230024pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12230024pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12230024pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12230024pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12230024pubmed:statusMEDLINElld:pubmed
pubmed-article:12230024pubmed:issn0192-415Xlld:pubmed
pubmed-article:12230024pubmed:authorpubmed-author:ShimadaYutaka...lld:pubmed
pubmed-article:12230024pubmed:authorpubmed-author:KashiwagiSeiz...lld:pubmed
pubmed-article:12230024pubmed:authorpubmed-author:HayashiJunJlld:pubmed
pubmed-article:12230024pubmed:authorpubmed-author:TerasawaKatsu...lld:pubmed
pubmed-article:12230024pubmed:authorpubmed-author:MantaniNaokiNlld:pubmed
pubmed-article:12230024pubmed:authorpubmed-author:SakaiShinyaSlld:pubmed
pubmed-article:12230024pubmed:authorpubmed-author:KainumaMosabu...lld:pubmed
pubmed-article:12230024pubmed:authorpubmed-author:ImaiKazuakiKlld:pubmed
pubmed-article:12230024pubmed:authorpubmed-author:KohtaKazufumi...lld:pubmed
pubmed-article:12230024pubmed:authorpubmed-author:MitsumaTadami...lld:pubmed
pubmed-article:12230024pubmed:issnTypePrintlld:pubmed
pubmed-article:12230024pubmed:volume30lld:pubmed
pubmed-article:12230024pubmed:ownerNLMlld:pubmed
pubmed-article:12230024pubmed:authorsCompleteYlld:pubmed
pubmed-article:12230024pubmed:pagination355-67lld:pubmed
pubmed-article:12230024pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:meshHeadingpubmed-meshheading:12230024...lld:pubmed
pubmed-article:12230024pubmed:year2002lld:pubmed
pubmed-article:12230024pubmed:articleTitleThe efficacy of herbal medicine (kampo) in reducing the adverse effects of IFN-beta in chronic hepatitis C.lld:pubmed
pubmed-article:12230024pubmed:affiliationDepartment of Japanese Oriental Medicine, Toyama Medical and Pharmaceutical University, Japan. Kainuma@ms.toyama-mpu.ac.jplld:pubmed
pubmed-article:12230024pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12230024pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12230024pubmed:publicationTypeControlled Clinical Triallld:pubmed